Results 111 to 120 of about 197,589 (314)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy

OncoImmunology, 2019
Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates ...
Tiziana Triulzi, Luca Forte, Viola Regondi, Martina Di Modica, Cristina Ghirelli, Maria Luisa Carcangiu, Lucia Sfondrini, Andrea Balsari, Elda Tagliabue   +8 more
doaj   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Scalable Engineering of Bio‐Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient‐Derived Models

Advanced Science, EarlyView.
Engineered extracellular vesicles displaying Ephrin‐B2 selectively target Ephrin‐B4–expressing ovarian cancer cells, enabling precise delivery in patient‐derived models. This scalable bio‐manufacturing platform reveals a versatile strategy to exploit Ephrin signaling for highly specific therapeutic payload delivery and motivates exploration of tailored
Nihar Godbole, Andrew Lai, Alexander Quinn, Marianne Gillard, Dominic Guanzon, Katherin Scholz‐Romero, Alexis Salas‐Burgos, Bastián Lillo Dapremont, Rohan Lourie, Naven Chetty, Richard Lobb, Kate Beecher, Amy E. McCart Reed, Kaltin Ferguson, Biao Sun, Yaowu He, John D. Hooper, Carlos Salomon   +17 more
wiley   +1 more source

HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor

, 2019
Monoclonal antibodies can effectively target to tumors in patients, as validated by antibody–drug conjugates (ADCs). The clinically used ADCs, nevertheless, are restricted to toxins only and suffer from low drug content, excessive use of antibody, and ...
Yifan Zhang (119570), Wenxing Gu, Shujing Yue (7444919), Yifan Zhang, Jeroen J. L. M. Cornelissen (7444922), Lin Ding, Lin Ding (211686), Huanli Sun (1483117), Huanli Sun, Jeroen J. L. M. Cornelissen, Zhiyuan Zhong (1403683), Zhiyuan Zhong, Shujing Yue, Wenxing Gu (4336930)   +13 more
core   +1 more source

Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies

Advanced Science, EarlyView.
This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander, Maria del Pilar Palacios Cisneros, Clara Certa, Megan Stierli, Katharina Beck, Nicolas Färber, Lisa Blank, Fiona Tanner, Eric Mühlberg, Sabrina Wohlfart, Christian Kleist, Jörg Huwyler, Gert Fricker, Walter Mier, Philipp Uhl   +14 more
wiley   +1 more source

Expression of TOPⅡα, TP53 and HER2 in Gastric Adenocarcinoma and Their Clinical Significance

Zhongliu Fangzhi Yanjiu, 2018
Objective To detect the expression of TOPⅡα, TP53 and HER2 in gastric adenocarcinoma tissuses, and to explore their inner relationship as well as their relationship with the clinicopathological characteristics of gastric adenocarcinoma patients.
MA Yihui, WANG Qingjie, GAO Hanqing, WANG Feng, CHEN Kuisheng   +4 more
doaj   +1 more source

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer

Cancer Research and Treatment
Purpose Dual anti–human epidermal growth factor receptor 2 (HER2) drugs have become the standard regimen for neoadjuvant systemic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 protein expression levels.Materials and Methods A total of 575 HER2-positive breast cancer ...
Lingjun Ma, Ran Zheng, Lingyun Xu, Ying Zhu, Hong Yin, Xiaoqing Zhang, Rong Deng, Jue Wang, Xiaoming Zha   +8 more
openaire   +2 more sources

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

PLOS ONE, 2015
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. Gene amplification in double minutes (DMs), which are extrachromosomal entities
Rocio Vicario, Vicente Peg, Beatriz Morancho, Mariano Zacarias-Fluck, Junjie Zhang, Águeda Martínez-Barriocanal, Alexandra Navarro Jiménez, Claudia Aura, Octavio Burgues, Ana Lluch, Javier Cortés, Paolo Nuciforo, Isabel T Rubio, Elisabetta Marangoni, James Deeds, Markus Boehm, Robert Schlegel, Josep Tabernero, Rebecca Mosher, Joaquín Arribas   +19 more
openaire   +4 more sources

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source